Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $199.06 | 6 | 73.8% |
| Education | $70.79 | 3 | 26.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $111.94 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $46.02 | 2 | $0 (2023) |
| EMD Serono, Inc. | $28.97 | 2 | $0 (2019) |
| AMAG Pharmaceuticals, Inc. | $24.77 | 1 | $0 (2018) |
| kaleo, Inc. | $24.38 | 1 | $0 (2018) |
| PFIZER INC. | $18.50 | 1 | $0 (2019) |
| Celgene Corporation | $15.27 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15.27 | 1 | Celgene Corporation ($15.27) |
| 2023 | $25.57 | 1 | E.R. Squibb & Sons, L.L.C. ($25.57) |
| 2020 | $20.45 | 1 | E.R. Squibb & Sons, L.L.C. ($20.45) |
| 2019 | $159.41 | 4 | Amgen Inc. ($111.94) |
| 2018 | $49.15 | 2 | AMAG Pharmaceuticals, Inc. ($24.77) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/13/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.27 | General |
| Category: Hematology | ||||||
| 02/06/2023 | E.R. Squibb & Sons, L.L.C. | SPRYCEL (Drug) | Education | In-kind items and services | $25.57 | General |
| Category: Oncology | ||||||
| 08/14/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $20.45 | General |
| Category: Oncology | ||||||
| 12/18/2019 | EMD Serono, Inc. | Bavencio (Biological) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Oncology | ||||||
| 11/26/2019 | PFIZER INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2019 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $111.94 | General |
| Category: Oncology | ||||||
| 09/12/2019 | EMD Serono, Inc. | Bavencio (Biological) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: Oncology | ||||||
| 12/01/2018 | kaleo, Inc. | EVZIO (Drug) | Food and Beverage | Cash or cash equivalent | $24.38 | General |
| Category: OPIOID ANTAGONIST | ||||||
| 10/03/2018 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Education | In-kind items and services | $24.77 | General |
| Category: TREATMENT OF DYSPAREUNIA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 357 | 4,080 | $353,432 | $81,779 |
| 2022 | 8 | 319 | 2,468 | $230,684 | $59,340 |
| 2021 | 5 | 364 | 782 | $122,536 | $58,684 |
| 2020 | 4 | 297 | 728 | $111,757 | $44,527 |
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 134 | 558 | $231,570 | $57,688 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 47 | 47 | $27,777 | $6,184 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 46 | 117 | $36,153 | $5,983 | 16.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 25 | 30 | $18,150 | $4,404 | 24.3% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Office | 2023 | 13 | 18 | $13,356 | $3,462 | 25.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 17 | $6,681 | $1,732 | 25.9% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 27 | 32 | $14,304 | $1,491 | 10.4% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 25 | 3,040 | $3,040 | $333.80 | 11.0% |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | Office | 2023 | 11 | 203 | $1,627 | $290.57 | 17.9% |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | Office | 2023 | 13 | 18 | $774.00 | $208.98 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 103 | 289 | $88,145 | $22,380 | 25.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 86 | 197 | $80,376 | $21,947 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 54 | 54 | $31,320 | $7,472 | 23.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2022 | 14 | 16 | $9,504 | $3,055 | 32.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 19 | $7,315 | $2,037 | 27.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 17 | $4,964 | $1,382 | 27.8% |
| 71260 | Ct scan of chest with contrast | Office | 2022 | 14 | 16 | $7,200 | $896.64 | 12.5% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2022 | 16 | 1,860 | $1,860 | $170.08 | 9.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 259 | 671 | $97,268 | $48,075 | 49.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 47 | 47 | $15,020 | $6,307 | 42.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 24 | 24 | $6,423 | $2,348 | 36.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 22 | 26 | $2,167 | $1,209 | 55.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 14 | $1,658 | $745.37 | 45.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 206 | 637 | $91,728 | $36,210 | 39.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 38 | 38 | $11,704 | $4,533 | 38.7% |
About Dr. Deepjot Singh, MD
Dr. Deepjot Singh, MD is a Medical Oncology healthcare provider based in Coupeville, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417977083.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deepjot Singh, MD has received a total of $269.85 in payments from pharmaceutical and medical device companies, with $15.27 received in 2024. These payments were reported across 9 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($199.06).
As a Medicare-enrolled provider, Singh has provided services to 1,337 Medicare beneficiaries, totaling 8,058 services with total Medicare billing of $244,329. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Practice Information
- Specialty Medical Oncology
- Location Coupeville, WA
- Active Since 07/19/2006
- Last Updated 12/02/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1417977083
Products in Payments
- Kyprolis (Biological) $111.94
- Bavencio (Biological) $28.97
- SPRYCEL (Drug) $25.57
- INTRAROSA (Drug) $24.77
- EVZIO (Drug) $24.38
- OPDIVO (Biological) $20.45
- XTANDI (Drug) $18.50
- REBLOZYL (Biological) $15.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.